10 results about "Immunomodulatory protein" patented technology

Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided.

The present invention relates to the use of GMI (Ganoderma immunomodulatory protein) derived from Ganoderma lucidum spores in the preparation of pharmaceuticals and food products. The aforementioned pharmaceuticals and food products are prepared using GMI produced by fermentation of a genetically modified Pichia pastoris strain Ey72, and are intended for the treatment, prevention, or amelioration of pulmonary fibrosis.

To provide a variant ICOS ligand (ICOSL) polypeptide.SOLUTION: Provided is a variant ICOSL polypeptide that comprises one or more amino acid modifications in an immunoglobulin superfamily domain of an ICOSL polypeptide, the variant ICOSL polypeptide being a truncated extracellular domain comprising: a contiguous sequence of amino acids comprising amino acids 1 to 112; and a C-terminal truncation of at least 25 amino acids, based on the ICOSL extracellular domain sequence represented by a specific sequence.SELECTED DRAWING: Figure 13A

The invention discloses an immunomodulatory polypeptide and application thereof. The invention discovers that a peptide fragment KR5 obtained by enzymolysis of flammulina velutipes immunomodulatory protein FIP-fve and a part of homologous peptide fragments from different fungus sources both have better immunomodulatory characteristics, and the amino acid sequence of the peptide fragment KR5 is B-Y-J-YR. After the KR5 is subjected to reversed-sequence overturning and modification transformation, the immune activation effect of the obtained D-configuration polypeptide and modified polypeptide is unchanged compared with that of the KR5, and both the D-configuration polypeptide and the modified polypeptide are superior to that of the flammulina velutipes immunomodulatory protein FIP-fve. In a mouse CT26 colorectal cancer model, the rk5 can significantly inhibit tumor growth, and the therapeutic effect is equivalent to that of a PD-L1 antibody. The FIP active polypeptide provided by the invention provides a theoretical basis for exploring pharmacodynamic substances and action mechanisms of FIP, provides candidate drugs for tumor immunologic diagnosis and treatment, and has a good application prospect and a relatively high economic value.

The invention relates to an engineering probiotic oral nano capsule modified by a nano material as well as a preparation method and application of the engineering probiotic oral nano capsule. The engineering modification of probiotics comprises the steps of knocking out a clbA gene and overexpressing an Sj16 protein and a GbpA protein. The intestinal adhesion protein GbpA is expressed on the surface of the engineered escherichia coli, an ultrasonic response element is integrated, the immunomodulatory protein Sj16 can be controllably expressed under ultrasonic stimulation, the adhesion and colonization capacity of the engineered escherichia coli in the intestinal tract is enhanced through engineered modification, the immune balance of the intestinal mucosa is cooperatively regulated, and the immunomodulatory effect of the engineered escherichia coli is improved. The generation and secretion of pathogenic autoantibodies from intestinal tracts are obviously reduced. On the basis, the molybdenum-based monatomic nano-material is functionally modified by using an enteric polymer, and a uniform nano-material-polymer composite coating is formed on the modified probiotics by adopting an in-situ wrapping technology, so that the nano-material-polymer composite coating shows a remarkable effect in the aspect of treating the autoimmune nephritis and has an important clinical application value.

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunomodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

Disclosed herein are recombinant mesenchymal stromal cells (e MSCs) that expresses one or more immunomodulatory proteins or polypeptides as well as mixed cell populations that include the eMSCs and one or more cell types distinct of the eMSC, such as islet cells or islets. Also disclosed are implantable cell culture devices that include eMSCs or the mixed cell populations. The eMSCs can be used to improve survival of transplanted cells (such as an allograft), and more particularly to methods of modifying T cell response to an allograft and treating a diabetic subject.

The invention relates to an immunomodulatory protein and application thereof in medicine preparation, and belongs to the technical field of biological medicine. The invention discloses application of a recombinant protein p33 in preparation of a medicine for treating autoimmune diseases. The diseases comprise systemic lupus erythematosus, skin type lupus erythematosus, acute graft versus host disease and chronic graft versus host disease. The human recombinant p33 protein is used for intravenous injection treatment of systemic lupus erythematosus mice and graft-versus-host disease mice for the first time, it is found that the recombinant p33 protein can significantly reduce lymphocyte cell proliferation and inhibit pathological damage of organs such as kidneys and livers caused by inflammatory cells, and therefore the effect of treating the systemic lupus erythematosus mice and the graft-versus-host disease mice is achieved. In addition, the recombinant p33 protein can relieve SLE mouse skin lesion and GVHD inflammation, and the survival rate is increased.